This study was undertaken to investigate the efficacy of 5% PABA cream using mouse ear swelling reaction(ESR). Mice were exposed to 100mJ/cm of UVB, five times a week for four weeks, on the both ventral aspect of the ear, with application of 5% PABA cream on the right ear. The results were as follows : 1. The intensity of ear swelling reaction of 5% PABA protected group was reduced greater than unproteeted group after the first 3 days of UUR. 2. The intensity of ear swelling reached at peak after 1 week of the ultraviolet radiation. Thereafter it has decreased gradually the following 4 weeks. The difference of ear swelling between the two groups was the greatest after 1 week, and the sunscreening efficacy of 5% PABA cream has remained persisted for 4 weeks. 3. The number of mice which have shown severe inflarnmatory response after ultravioiet radiation was more in unprotected group than that in 5% PABA protected group. 4. Determination of mouse ESR is considered a good method for the evaluation of longterm efficacy of sunscreen preparation.
4-Aminobenzoic Acid ; Animals ; Ear* ; Mice*

Para-aminobenzoate (PABA) is an important chemical for organic synthesis and extensively used in pharmaceutical and dye industry. In recent years, PABA has received increasing attention as a potential component of high-strength polymer. In Escherichia coli, three genes of pabA, pabB and pabC are responsible for PABA production from chorismate in folate synthetic pathway. However, E. coli does not accumulate or accumulates very few amounts of PABA under normal growth condition. In this study, the tyrosine-producing E. coli TYR002 constructed previously was used as the starting strain for developing PABA-producing strain. First, the activity of bifunctional chorismate mutase/prephenate dehydrogenase TyrA in E. coli TYR002 was weakened to reduce the production of tyrosine. Then, three different constitutive promoters were used to regulate the expression of pabA, pabB and pabC in recombinant plasmid which was transformed into E. coli for improving PABA production. The shake-flask fermentation showed that the different combination of constitutive promoters significantly affected the production of PABA, and the highest shake-flask fermentation titer was 0.67 g/L. After further condition optimization, the engineered E. coli produced 6.4 g/L PABA under 5 L fed-batch fermentation. This study could be a good reference for improving microbial production of PABA.
4-Aminobenzoic Acid ; Escherichia coli ; Plasmids

OBJECTIVETo study the effect of para-aminobenzoic acid (PABA) on the growth and metabolism of Porphyromonas gingivalis (P.g).

METHODSAfter adding different concentrations of PABA into the medium, anaerobic technique was applied to culture P.g. The products' A value and action of TLP was assayed, and P.g grew in the medium was observed by a scanning electron microscope.

RESULTSPABA promoted the growth of P.g and action of TLP, which would reach the highest level when PABA was 1 mg/L, and would decrease with the increasing of concentration of PABA. When the concentration arrived at 100 mg/L, PABA had no effect on them. In the mean time, PABA had effect on the form and adherence of P.g. When the concentration was 1 mg/L and 100 mg/L, this effect was strong, but as the concentration was 10 mg/L, the effect disappeared.

CONCLUSIONSPABA influences the growth and metabolism of P.g, which indicate that Streptococcus sanguis has regulative effect on the microecology of subgingival plaque.

Benzophenones are aromatic ketone derivatives of dibenzoylmethane, exhibiting absorption characteristics not only in the UVC and UVB spectral ranges but also in part of the UVA range, up to 360nm. They are commonly used for extending the spectrum of photoprotection. Benzophenone-3, one of the most popular benzophenones, is the most common cause of sunscreen allergy as well as a substitute of PABA. We report a case of photoallergic contact dermatitis due to benzophenone-3 of sunscreen.
4-Aminobenzoic Acid ; Absorption ; Benzophenones ; Dermatitis, Photoallergic* ; Hypersensitivity

PURPOSE: To evaluate the effect and improvement of potassium aminobenzoate (500 mg Peyron capsule) in oral therapy for Peyronie's disease. MATERIALS AND METHODS: From February 2011 to September 2011, 31 patients with Peyronie's disease received potassium aminobezoate (500 mg Peyron capsules) and were divided into two groups. Group 1 (N=10) received potassium aminobezoate (500 mg Peyron capsule) 3 g four times daily without previous treatment of Peyronie's disease, while group 2 (N=21) received the same drug with previous treatment of Peyronie's disease (10 mg Tamoxifen +300 mg L-carnitine two times daily). Outcomes were assessed by subjective symptom change, pain relief, resolutions of the plaque, and curvature. RESULTS: After 3 months, there were no significant improvements in clinical outcomes of either group and among all the patients, 23 stopped taking potassium aminobezoate (23/31, 74%). The reasons for ceasing the therapy were gastrointestinal trouble (8/23, 35%), too many doses to take (7/23, 30%), ineffectiveness (6/23, 26%), and high price (2/23, 9%). CONCLUSIONS: Athough the etiology of Peyronie's disease has not been elucidated, potassium aminobenzoate in therapy of Peyronie's disease has been used. The use of this medication has the limitations of gastrointestinal trouble, ineffectiveness, too many doses, and high price. Further evaluations of the effect and appropriate dosing of potassium aminobenzoate are needed.
4-Aminobenzoic Acid ; Carnitine ; Humans ; Male ; Penile Induration ; Potassium ; Tamoxifen

We performed a bentiromide test in 25 patients with chronic pancreatitis and 7 normal controls to evaluate pancreatic exocrine function, and compared the test results of patients with their endoscopic retrograde pancreatography(ERP) findings. The cumulative 6-hour recovery rate of para-aminobenzoic acid(PABA) in the urine was significantly lower in patients with chronic pancreatitis(55.8 +/- 24.2%) than in controls(82.0 +/- 10.0%). Among 25 patients with chronic pancreatitis, however, 7 patients showed normal recovery rates of PABA. Pancreatograms of the patients represented 4 mild changes, 5 moderate changes, and 16 marked changes. The average 6-hour recovery rates of PABA of the groups were 56.9 +/- 21.6%, 78.4 +/- 10.5%, and 47.2 +/- 23.7%, respectively. Urinary PABA recovery rates were found subnormal as follows: 3(75%) in the mild changes group; 1(20%) in the moderate changes group; and 14(87.5%) in the marked changes group. We found hardly any correlation between the degree of functional impairment and the changes noted by ERP. These findings suggest that both the pancreatic function test and morphologic study are required to evaluate the degree of functional impairment in patients with chronic pancreatitis.
4-Aminobenzoic Acid/diagnostic use ; 4-Aminobenzoic Acid/analogs & derivatives* ; Adult ; Aged ; Bicarbonates/metabolism ; Chronic Disease ; Comparative Study ; Female ; Human ; Male ; Middle Age ; Pancreas/radiography* ; Pancreatitis/diagnosis*

The purpose of this study is to evaluate the effectiveness of these para-amino- benzoate, benzophenone and cinnamate sunscreens in the same base(cream) and the effect of concentration on sun protection with three different concentrations(2 5%, 5. 0% and 7. 5%.). Twenty-one normal healthy Korean-men, majority(2. 5%) of whom have skin type iv or v, were applied to their untanned back with above prepared nine different sunscreens and calculated individual sun protection factor (SPF) of these different sunscreens. The test results can be summarized as follows: 1. In the para-aminobenzoic acid, the mean SPF, of concentrations were 7. 33+2. 87, 7.35+2. 89 and 7. 37+2. 88 no significant difference. 2. In the benzophenone, the mean SPF of all of 2. 5M, ntrations was 3.43 t0. 85. 3 In the cinnamate, the mean SPF of all of 2. 5% 5. O%
4-Aminobenzoic Acid ; Benzoates ; Skin* ; Solar System ; Sun Protection Factor ; Sunscreening Agents*

The sunscreening effect can be varied according to the vehicles. Therefore the purpose of this study is to compare the effect of vehicles(bases) on sun protection in p-aminobenzoic acid, cinnamate and benzophenone sunscreens with same concentration (2.5%), We included ointment (white petrolatum), cream (hydrophilic), milky lotion and alcohol as the sunscreen vehicles. The test results can be summarized as follows: We could not recognize a sunscreening effect of sunscreen vehicles which did not contain sunscreening agent. In the case of p-aminobenzoic acid, the mean sun protection factor was higher in the sequence of cream, milky lotion, alcohol, ointment, each showing 9, 95+/-3.67, 8.09+/-2.56, 5.14+/-1.45, 4.35+/-1.46 respectively. In the case of cinnamate, the mean sun protection factor was higher in the sequence of cream, ointment, milky lotion, alcohol, each showing 6 46+/-1.89, 5.42+/-1.49, 4.82+/-1.84, 4.05+/-1.45 respectively. 4. In the case of benzophenone, the mean sun protection factor was higher in the sequence of cream, alcohol, ointment, milky lotion, each showing 5 .26+/-1.56, 4.94+/-1.24, 4.56+/-1.71, 4.18+/-1.23 respectively.
4-Aminobenzoic Acid ; Skin* ; Solar System ; Sun Protection Factor ; Sunscreening Agents

We present a case which seems identical to REM(Reticular Erythematous Mucinosis) syndrome in 26 year-old male. The lesion was initiated about 2 years ago and waxed and waned. The clinical findings were localized, grouped, erythematous papules and vesicles on the anterior middle chest with intermittent mild itching. Histopathology showed normal epidermis, extensive mucin deposition, telangiectasia and mild perivascular round cell infiltrations on the upper dermis. The mucin was stainable with alcian blue at pH 2. 5, but was not stained by either PAS or mucicarmine. Skin lesions were not responded to the oral steroid, but improved slowly after topical application of 5% para-aminobenzoic acid in ethanol for 9 months. The lesion does not recur until present time.
4-Aminobenzoic Acid ; Adult ; Alcian Blue ; Dermis ; Epidermis ; Ethanol ; Humans ; Hydrogen-Ion Concentration ; Male ; Mucins ; Pruritus ; Skin ; Telangiectasis ; Thorax

PURPOSE: This study was designed to evaluate the efficacy of medical treatment of Peyronie's disease. MATERIALS AND METHODS: A total of 109 patients with Peyronie's disease who had been treated from January 2011 to December 2014 were retrospectively reviewed in this study. Forty-four patients (Group 1) were treated with 12 mg of potassium para-aminobenzoate daily. Sixty-five patients (Group 2) were treated with combination therapy: tamoxifen (20 mg) and acetyl-L-carnitine (300 mg) twice daily in addition to a phosphodiesterase type 5 inhibitor. Ability to perform sexual intercourse, pain during erection, size of plaque, and penile curvature angle were assessed. RESULTS: In Group 1, 30 of 44 patients (68.2%) discontinued treatment within 12 weeks, while 5 patients (7.7%) in Group 2 discontinued treatment. Pain during erection and plaque size were improved in both groups but showed no statistical difference due to the high dropout rate in Group 1. In both groups, penile curvature was improved, but demonstrated no statistical difference between the treatment groups. However, combination therapy demonstrated a better response rate in patients whose penile curvature angle was less than 30° (44.4% vs. 79.1%, p=0.048). The rate of successful sexual intercourse was significantly higher in Group 2 (42.8% vs. 78.3%, p=0.034). The number of patients who underwent surgical correction despite medical treatment was significantly higher in Group 1 (35.7% vs. 13.3%, p=0.048). CONCLUSIONS: Early medical combination therapy in Peyronie's disease may present better results in patients whose curvature angle is less than 30°.
4-Aminobenzoic Acid ; Acetylcarnitine ; Carnitine* ; Coitus ; Drug Therapy, Combination ; Humans ; Male ; Patient Dropouts ; Penile Induration* ; Potassium* ; Retrospective Studies ; Tamoxifen*